AUD

Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression

Retrieved on: 
Wednesday, March 27, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Depression, Atypical depression, Data analysis, MDD, Patient, Beckley Foundation, DSM-IV codes, TRD, Treatment, Drug development, Safety, Phase, FDA, 5-MeO-DMT, Pharmaceutical industry

95% of events were mild or moderate, and no serious adverse events were reported which is broadly consistent with Phase I findings .

Key Points: 
  • 95% of events were mild or moderate, and no serious adverse events were reported which is broadly consistent with Phase I findings .
  • Acute effects were resolved and patients were deemed dischargeable within an average time of less than 2 hours.
  • Our single dose treatment model enables a short treatment duration which positions BPL-003 as a potentially exciting and scalable treatment opportunity.
  • The company’s lead compound, BPL-003, is a novel, synthetic 5-MeO-DMT benzoate salt candidate currently under investigation for the treatment of Treatment Resistant Depression (TRD) and Alcohol Use Disorder (AUD).

AM Best Withdraws Credit Ratings of The Hollard Insurance Company Pty Ltd

Retrieved on: 
Thursday, March 21, 2024
Insurance, Professional Services, ERM, HHA, Communication, ALL, News, Acquisition, Credit, AM Best, HIC, Weather

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of The Hollard Insurance Company Pty Ltd (HIC) (Australia).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of The Hollard Insurance Company Pty Ltd (HIC) (Australia).
  • Concurrently, AM Best has withdrawn these ratings as the company has requested to no longer participate in AM Best’s interactive rating process.
  • The ratings also factor in a neutral impact from the company’s ownership by Hollard Holdings Australia Pty Ltd (HHA).
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .

Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured

Retrieved on: 
Wednesday, March 13, 2024
High court, Patient, Acquisition, Mammography, Scheme, Therapy, USD, Medical device

SEOUL, South Korea, March 13, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a significant update on its acquisition of Volpara Health Technologies (Volpara; ASX:VHT). An initial order from the High Court of New Zealand has been granted, and all necessary consents under New Zealand's Overseas Investment Act and Overseas Investment Regulations have been secured to facilitate the implementation of the Scheme. The initial order signals approval and mandates the upcoming shareholder meeting as the next step.

Key Points: 
  • An initial order from the High Court of New Zealand has been granted, and all necessary consents under New Zealand's Overseas Investment Act and Overseas Investment Regulations have been secured to facilitate the implementation of the Scheme.
  • The initial order signals approval and mandates the upcoming shareholder meeting as the next step.
  • This acquisition encompasses a total of 254 million shares, amounting to a substantial deal valued at about AUD 292 million (USD 193 million).
  • "We're pleased to announce the High Court's approval, a significant step in our remarkable journey.

QEP Completes Sale Of Australia/New Zealand Business

Retrieved on: 
Monday, March 4, 2024
Consent, Amendment, Release, Bank, Growth, Sale, BOCA, Committee, Security agreement, OTCQX, QEP, Bank of America

CO., INC. (OTCQX: QEPC) (the “Company” or “QEP”) today announced that it has completed the previously announced sale of its Australia and New Zealand business (the “ANZ Business”) to QEP Australasia Pty.

Key Points: 
  • CO., INC. (OTCQX: QEPC) (the “Company” or “QEP”) today announced that it has completed the previously announced sale of its Australia and New Zealand business (the “ANZ Business”) to QEP Australasia Pty.
  • Bruce Maclaren has served as the Managing Director of the ANZ Business for 20 years including a period of three years as CEO European Operations for QEP based in the UK.
  • Tony Lei has also been involved with QEP for over 20 years as a valued supplier to the ANZ Business and QEP’s other businesses around the world.
  • Executive Chairman of QEP, Lewis Gould, stated, “The closing of this transaction is another significant step to realign our global footprint to drive long-term stockholder value.

Puma Announces a Creative Deal to Unlock Value of its Assets in New Brunswick

Retrieved on: 
Monday, March 4, 2024
Acquisition, OTCQB, NSR, Caribou Mine, TSX Venture Exchange, Prospectus, News, TSX, Sale, Option, PUMA, CAD, Project, ASX, Attention, Contract management, CCI, Development, Australian Securities Exchange, VWAP

Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.

Key Points: 
  • Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.
  • The sale of the Chester and Turgeon Projects to Raptor will allow Puma to further monetize its copper assets and unlock their value.
  • We’re always looking to increase shareholder value and creative ways to finance and control share dilution.
  • The objective for Puma is to receive from Raptor the same consideration value as the one that it negotiated in its initial option deal with Canadian Copper, of which CAD $2M remains receivable.

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Retrieved on: 
Saturday, March 2, 2024
Sale, Exercise, Regulation D, Form, Form S-1, Disorder, Act, Addiction, Security (finance)

The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.

Key Points: 
  • The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.
  • The gross proceeds to the Company from the exercise of the warrants are expected to be $3,530,500, prior to deducting placement agent fees and estimated offering expenses.
  • In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to 2,300,000 shares of common stock.
  • The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

Monument Reports Second Quarter Fiscal 2024 (“Q2 FY2024”) Results

Retrieved on: 
Friday, March 1, 2024
Odyssey, Acquisition, Monument, DMT, Total, Gabanintha, Western Australia, Tph, YTD, Mining, Retirement, Sale, Gold, London Bullion Market Association, TSF, Public expenditure, Atlas, Economics, Atlas Copco, Depreciation, Cryptocurrency

The mill processed 192,217 tonnes of sulphide ore, achieving a head grade of 1.55g/t and a recovery rate of 71.10%.

Key Points: 
  • The mill processed 192,217 tonnes of sulphide ore, achieving a head grade of 1.55g/t and a recovery rate of 71.10%.
  • Availability of the flotation plant also improved at 90% during Q2 2024 as a result of ongoing optimization.
  • Accommodation and catering facilities were fully operational during the quarter and equipped to support administrative, exploration, and mining activities.
  • Both Monument and Odyssey agreed to defer the payment by six months after the date of satisfaction of the milestone, specifically by February 2, 2024.

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024
Therapy, Reward, Alcoholism, Ministry, NET, Serotonin, Dopamine, Norepinephrine, Safety, MEAI, CWY, Patient, Clinical trial, Yale school, DAT, Psychiatry, Sheba Medical Center, Research, Pharmaceutical industry

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Euro Manganese Inc. Engages North American and Australian Communications Advisors

Retrieved on: 
Wednesday, February 21, 2024
TSX Venture Exchange, E06, Marketing, EMN, OTC Markets Group, JMM, CAD, ASX, Australian Securities Exchange, Frankfurt Stock Exchange

VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") is pleased to announce the appointment of North American and Australian investor relations advisors to assist the Company in raising greater awareness within the investment community.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") is pleased to announce the appointment of North American and Australian investor relations advisors to assist the Company in raising greater awareness within the investment community.
  • The Company has engaged LodeRock Advisors Inc. ("LodeRock") effective February 8, 2024 as its investor relations advisor in North America.
  • Concurrently, effective February 14, 2024, the Company has appointed Jane Morgan Management Pty Ltd. ("JMM") as its investor relations advisor in Australia.
  • Neither LodeRock nor JMM are current shareholders of the Company.

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Surgery, Health Technology, General Health, Clinical Trials, Cardiology, The Alfred Hospital, USD, Multimedia, University of Queensland, The Texas Heart Institute, University, FDA, Cancer, Hospital, IDE, Artificial heart, Griffith University, Heart failure, MRFF, Fatigue, TAH, Patient, Monash University, Survival, Periodic breathing, EFS, Pharmaceutical industry

BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.

Key Points: 
  • BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
  • View the full release here: https://www.businesswire.com/news/home/20240220429887/en/
    BiVACOR® Total Artificial Heart (TAH) in Surgeon's Hands (Photo: Business Wire)
    Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR.
  • The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device.
  • “There is a huge gap between available treatment options and the number of patients with severe heart failure.